Haier Biomedical announced plans to repurchase shares through centralized competitive trading, with the buyback amount ranging from 50 million to 100 million yuan. The maximum repurchase price is set at 46 yuan per share. All repurchased shares will be used to reduce registered capital. The buyback period is within 12 months after approval by the shareholders' meeting. In the first quarter of 2026, Haier Biomedical achieved revenue of 652 million yuan and net profit attributable to the parent company of 79.46 million yuan.
Qingdao Haier Biomedical Co LtdCompany announces share buyback of 50-100 million yuan to reduce registered capital, which is typically viewed as positive for shareholders.